Anthera Pharmaceuticals

San Mateo, CA

Anthera Pharmaceuticals is a pharmaceutical development company focused on the development and advancement of promising clinical products for the treatment of serious inflammatory diseases. Anthera's lead products have the potential to address a variety of inflammatory diseases including: acute lung injury, acute respiratory distress syndrome, acute chest syndrome, acute coronary syndrome, atherosclerosis, chronic obstructive pulmonary disease and psoriasis.

Athersys

Cleveland, OH

Athersys is a biopharmaceutical and regenerative medicine company that has established a pipeline of therapeutic product development programs in multiple disease areas including pharmaceutical programs focused on obesity and CNS (cognition, attention) and regenerative medicine programs focused on cardiovascular disease, stroke, hematological and immune disorders.

Bayhill Therapeutics

San Mateo, CA

Biopharmaceutical company focused on the translation of research into therapeutics for the treatment of autoimmune diseases. Bayhill's lead compound, an antigen-specific immunotherapy aimed at treating multiple sclerosis, is currently in Phase I clinical trials. A second antigen-specific compound for Type I diabetes and an oligonucleotide therapeutic are both in late preclinical testing.

BrainCells

San Diego, CA

BrainCells, INC (BCI) is a leading-edge neurogenesis-based drug discovery and development company targeting novel therapies for depression, mood disorders and other CNS diseases. The company is developing a neurogenesis platform for profiling and selecting drug candidates. BCI believes that the platform represents a major improvement in the predictive power of pre-clinical models for CNS disorders and will facilitate a paradigm shift in the way CNS drugs are discovered.

CardioDx

Palo Alto, CA

CardioDx is a cardiovascular genomic diagnostics company that develops clinically validated genomic tests to aid in assessing and tailoring care of individual patients with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias and heart failure.

CeNeRx BioPharma

Cary, NC

CeNeRx is developing innovative treatments for diseases of the central nervous system. The company's most advanced compound, a reversible inhibitor of monoamine oxidase, is undergoing Phase 2 clinical trials for the treatment of major depressive disorder. CeNeRx is also developing a pipeline of selective cannabinoid compounds that have completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma, and obesity.

Cequent Pharmaceuticals

Cambridge, MA

Early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.

CoLucid Pharmaceuticals

Indianopolis, IN

CoLucid Pharmaceuticals is a development stage biopharmaceutical company developing and discovering therapeutics that will be used to treat neurological dysfunctions. CoLucid develops pharmaceuticals with novel mechanisms of action to treat migraine headaches. The company also possesses a robust chemistry platform that will produce unique bifunctional neuromodulators to treat indications such as Alzheimer's disease.

Emerald BioAgriculture

Lansing, MI

Bioagriculture company developing, manufacturing and marketing biological and biochemical agents to improve crop yields, enhance quality, combat disease and fight pests. The company's lead product, AuxiGro®, is the first yield increasing biochemical to be registered by the California Department of Pesticide Regulation.

FlowCardia

Sunnyvale, CA

Medical device company that is developing a catheter for the treatment of chronic total occlusions (CTOs) of coronary arteries. Utilizing a technology known as high frequency mechanical recanalization, the company's CROSSER™ System safely and quickly breaks up CTOs allowing subsequent stent placement or balloon angioplasty and avoiding the trauma of cardiac surgery. Clinical trials are underway in Europe.

Genstruct

Cambridge, MA

Systems biology drug discovery company that deploys its mechanism discovery platform, Molecular Epistemics™, independently and in partnerships with pharmaceutical companies to streamline drug discovery and improve clincial trial design and implementation. Pappas Ventures II originally invested in Incellico, Inc. which was acquired in July 2003 by Genstruct.

Gentis

Wayne, PA

Gentis is a biomaterials and orthopedics company that has developed and is testing a potentially breakthrough, non-fusion technology for the treatment of spinal disc disease. Gentis's lead product is DiscCell, a proprietary, injectable, in-situ polymerizing spinal nucleus augmentation technology.

LipoScience

Raleigh, NC

Diagnostic company utilizing nuclear magnetic resonance (NMR) spectroscopy to measure the size and quantity of lipoprotein particles in blood. The company's NMR LipoProfile® blood test is intended to provide a better indication of the risk of developing cardiovascular heart disease than the standard cholesterol test measurements of 'good' and 'bad' cholesterol. The company currently markets and sells the NMR LipoProfile test to physicians, other healthcare professionals, diagnostic laboratories and clinical research clients.

Liquidia Technologies

Research Triangle Park, NC

Liquidia utilizes a proprietary technology platform to design and manufacture highly precise micro- and nanoparticles that allow for the delivery of biological and small molecule therapeutics. Initial programs include siRNA delivery, inhaled therapeutics, and vaccines.

MethylGene

Montreal, Quebec

TSE: MYG

Biopharmaceutical company focused on the discovery, development and commercialization of novel enzyme inhibitors for the treatment of cancer and infectious diseases. The company uses functional genomics to validate enzyme targets and uses rational drug design and medicinal chemistry to design, synthesize and optimize enzyme inhibitors.

Optherion

New Haven, CT

Optherion, Inc. is an early-stage biotechnology company that is developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on recent scientific discoveries linking certain genes to AMD.

Plexxikon

Berkeley, CA

Drug discovery company that utilizes a structural proteomics approach to discover novel pharmaceuticals. Using high-throughput X-ray crystallography, the company screens for novel chemical backbones known as scaffolds. The scaffolds are then co-crystallized with drug targets leading to high quality drug leads. Plexxikon has collaborations in place with Genentech, Inc. and Wyeth Pharmaceuticals.

Sensys Medical

Chandler, AZ

Developer of non-invasive technology for blood glucose monitoring. Once cleared by the Food and Drug Administration, the technology will provide a painless method to collect data for proactive use in controlling diabetes.

Syndax Pharmaceuticals

Waltham, MA

Syndax is an oncology-focused biopharmaceutical company that is developing novel therapies in optimized, mechanistically driven combination regimens.

TyRx

Monmouth Junction, NJ

Medical device company developing a range of drug-eluting implantable devices based on proprietary tyrosine polymer technology licensed from Rutgers University. The company's lead product is AIGIS-Rx™, an antibiotic-eluting mesh envelope into which pacemakers and defibrillators can be inserted prior to surgical implantation, thereby reducing the risk of post-procedure infection.